Home > Microtubule/Tubulin & Microtubule/Tubulin & > Vinorelbine Tartrate

Vinorelbine Tartrate

酒石酸长春瑞滨

Vinorelbine ditartrate (长春瑞滨双酒石酸盐; KW-2307) 是抗有丝分裂剂，能抑制Hela细胞增殖，IC50为1.25 nM。

目录号
EY1793
EY1793
EY1793
EY1793
纯度
99.61%
99.61%
99.61%
99.61%
规格
5 mg
10 mg
25 mg
50 mg
原价
320
500
1100
1820
售价
320
500
1100
1820
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

    ~10 mg/kgi.p.

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Fellous A, et al. Semin Oncol. 1989, 16(2 Suppl 4), 9-14.

    分子式
    C53H66N4O20    		 分子量
    1079.11    		 CAS号
    125317-39-7    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    100 mg/mL    		 Water
    100 mg/mL    		 Ethanol
    100 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00176488 Breast Cancer Drug: epirubicin|Drug: vinorelbine University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey Phase 2 2003-06-01 2017-02-20
    NCT00912275 Metastatic Breast Cancer Drug: lapatinib plus oral vinorelbine National Taiwan University Hospital|GlaxoSmithKline Phase 1|Phase 2 2009-05-01 2012-11-15
    NCT02985203 Lung Neoplasm Malignant Drug: Vinorelbine Oral Guangdong Association of Clinical Trials Phase 2 2016-11-01 2017-02-23
    NCT03007992 Metastatic Breast Cancer Drug: Vinorelbine Johannes Gutenberg University Mainz|Pierre Fabre Pharma GmbH Phase 2 2016-12-01 2017-02-08
    NCT01497860 Low-grade Glioma Drug: Vinorelbine Eugene Hwang|Children's Research Institute Phase 2 2011-07-01 2015-07-10
    NCT02139904 Mesothelioma Drug: Vinorelbine|Other: Active Symptom Control Lisette Nixon|Wales Cancer Trials Unit|Pierre Fabre Laboratories|Velindre NHS Trust Phase 2 2014-08-01 2014-05-13
    NCT02144194 Breast Cancer Drug: Vinorelbine-Docetaxel|Drug: Vinorelbine Cancer Research Group - Collaborative Group, Beirut, Lebanon. Phase 2 2012-03-01 2017-02-07
    NCT00702182 Non-Small Cell Lung Cancer Drug: Vinorelbine (Navelbine)|Drug: Vinorelbine (Navelbine)|Drug: Erlotinib National Cancer Centre, Singapore Phase 1 2008-04-01 2012-10-17
    NCT00003828 Melanoma (Skin) Drug: vinorelbine Southwest Oncology Group|National Cancer Institute (NCI) Phase 2 1999-05-01 2012-08-20
    NCT02197637 Low-Grade Glioma Drug: ORAL VINORELBINE Centre Oscar Lambret|National Cancer Institute, France|Pierre Fabre Laboratories Phase 2 2014-05-01 2016-07-04
    NCT00706069 Metastatic Breast Cancer Drug: Vinorelbine oral|Drug: Capecitabine Hellenic Oncology Research Group|University Hospital of Crete Phase 1 2008-06-01 2009-12-14
    NCT00870532 Non-Small Cell Lung Cancer Drug: oral vinorelbine|Drug: sorafenib National Cancer Centre, Singapore Phase 1 2008-06-01 2013-11-01
    NCT00432562 Breast Cancer|Non-small Cell Lung Cancer|Non-Hodgkins Lymphoma Drug: Vinorelbine Tartrate Mast Therapeutics, Inc.|Synteract, Inc.|Thywill Latam Solutions SRL|OCASA Soluciones Logsticas S.A.|Worldwide Clinical Trials Phase 1 2007-02-01 2012-01-19
    NCT00958724 Advanced Malignant Solid Tumors Drug: treatment with neratinib (HKI-272) + vinorelbine Puma Biotechnology, Inc. Phase 1 2009-07-01 2012-05-10
    NCT00801151 Malignant Solid Tumour Drug: Zolinza (vorinostat), vinorelbine Institut Claudius Regaud|Merck Sharp & Dohme Corp. Phase 1 2009-01-01 2010-05-19
    NCT02658084 Breast Cancer|Metastatic Breast Cancer Drug: Vinorelbine|Drug: Trastuzumab Emtansine University of Miami|Genentech, Inc. Phase 1|Phase 2 2016-10-01 2016-09-27
    NCT00602797 Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer Drug: vinorelbine tartrate|Drug: paclitaxel|Procedure: quality-of-life assessment|Other: questionnaire administration University of Nebraska|National Cancer Institute (NCI) Phase 2 2007-12-01 2014-04-01
    NCT01220284 Advanced Solid Tumors Drug: Satraplatin in combo with vinorelbine Southern Europe New Drug Organization|Agennix|Pierre Fabre Laboratories Phase 1 2008-02-01 2010-10-11
    NCT00513058 Breast Cancer Drug: Lapatinib|Drug: vinorelbine UNICANCER Phase 1 2007-06-01 2014-01-13
    NCT01196559 Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Drug: Vinorelbine and Gemcitabine The Catholic University of Korea|Korean Cancer Study Group Phase 2 2011-01-01 2015-02-14
    NCT02802748 Breast Cancer Drug: Oral Vinorelbine|Drug: Letrozole SOLTI Breast Cancer Research Group|Pierre Fabre Laboratories Early Phase 1 2016-07-01 2017-02-15
    NCT00017394 Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer Biological: bevacizumab|Drug: vinorelbine tartrate|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 2 2001-03-01 2013-01-16
    NCT00278070 Breast Cancer|Non Small Cell Lung Cancer|Prostate Cancer Drug: vinorelbine oral formulation Hellenic Cooperative Oncology Group|University of Ioannina Phase 2 2006-01-01 2008-02-27
    NCT00755170 Non Small Cell Lung Cancer Drug: Vinorelbine|Drug: Bevacizumab Hellenic Oncology Research Group|University Hospital of Crete Phase 2 2008-11-01 2016-10-03
    NCT00215462 Esophageal Cancer|Gastric Cancer|Stomach Cancer Drug: Vinorelbine Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center Phase 2 2000-06-01 2009-04-27

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：